Certificate Of Analysis For 2,5-Dimercapto-1,3,4-Thiadiazole Bulk Supply: Ensuring Compliance and Quality Assurance
- Comprehensive COA documentation is critical for verifying industrial purity, batch consistency, and regulatory alignment in pharmaceutical intermediates like 2,5-Dimercapto-1,3,4-thiadiazole.
- NINGBO INNO PHARMCHEM CO.,LTD. provides full traceability, validated synthesis routes, and DMF-ready COAs to support global compliance requirements.
- When sourcing high-purity 2,5-Dimercapto-1,3,4-thiadiazole, buyers must verify analytical data covering identity, assay, residual solvents, and heavy metals.
In the tightly regulated landscape of pharmaceutical manufacturing, the Certificate of Analysis (COA) for 2,5-Dimercapto-1,3,4-thiadiazole (CAS: 1072-71-5)—also known as 1,3,4-thiadiazole-2,5-dithiol or Bismuththiol—is not merely a quality document; it is a foundational element of supply chain integrity and regulatory compliance. As a key intermediate in cefazolin synthesis and other beta-lactam antibiotics, this compound demands rigorous analytical validation at every production stage.
Essential COA Components for Pharmaceutical Intermediates
A scientifically robust COA for bulk 2,5-Dimercapto-1,3,4-thiadiazole must include more than just an assay percentage. It should reflect adherence to ICH Q7 guidelines and align with pharmacopoeial standards (e.g., USP, EP). Key parameters typically verified include:
- Identity confirmation via FTIR, NMR, or HPLC retention time matching
- Assay purity (typically ≥98% on dry basis)
- Water content (Karl Fischer titration; often specified as <3%)
- Residual solvents from the manufacturing process (e.g., ethanol, toluene)
- Heavy metals (Pb, As, Cd, Hg) below ICH Q3D limits
- Related substances and degradation impurities
These metrics ensure that the material meets the stringent requirements for use in active pharmaceutical ingredient (API) synthesis. Notably, the industrial purity of 2,5-Dimercapto-1,3,4-thiadiazole directly impacts reaction yields and downstream purification costs—making COA transparency non-negotiable for cost-efficient scale-up.
How COA Supports Regulatory Filings (DMF, CEP, etc.)
Regulatory submissions such as Drug Master Files (DMFs) or Certificates of Suitability (CEPs) require complete documentation of starting materials. The COA serves as primary evidence of consistent quality and controlled synthesis route. For instance, NINGBO INNO PHARMCHEM CO.,LTD. employs a well-documented, scalable route involving cyclization of thioglycolic acid derivatives under controlled pH and temperature—ensuring minimal genotoxic impurities and reproducible crystallinity.
Each COA issued by NINGBO INNO PHARMCHEM CO.,LTD. includes batch-specific analytical chromatograms, method validation summaries, and reference to internal quality control protocols aligned with ISO 9001 and GMP standards. This level of detail enables seamless integration into client regulatory dossiers without additional vendor audits or requalification delays.
Verifying Batch Consistency and Traceability in Supply Chain
Global pharmaceutical supply chains demand end-to-end traceability. A compliant COA must link each batch of 2,5-Dimercapto-1,3,4-thiadiazole to its raw material origins, reactor logs, and final packaging records. This ensures that any deviation—however minor—can be investigated and contained rapidly.
NINGBO INNO PHARMCHEM CO.,LTD., as a premier global manufacturer, implements digital batch record systems that generate tamper-proof COAs with unique batch identifiers, manufacturing dates, and expiry timelines. This infrastructure supports just-in-time inventory models while maintaining full audit readiness for FDA, EMA, or PMDA inspections.
Technical Specifications: Typical COA Data for 2,5-Dimercapto-1,3,4-Thiadiazole
| Parameter | Specification | Test Method |
|---|---|---|
| Chemical Name | 2,5-Dimercapto-1,3,4-thiadiazole | IUPAC / CAS 1072-71-5 |
| Appearance | White to off-white crystalline powder | Visual inspection |
| Assay (on dry basis) | ≥98.0% | HPLC (UV detection) |
| Water Content | <3.0% | Karl Fischer Titration |
| Melting Point | 160–163°C (with decomposition) | DSC / Capillary method |
| Residual Solvents | Meets ICH Q3C Class 2 limits | GC-FID |
| Heavy Metals | <10 ppm total | ICP-MS |
| pH (1% aqueous solution) | 4.0–6.0 | pH meter |
Such granular data empowers procurement and quality assurance teams to validate supplier claims objectively. Moreover, consistent COA formatting across batches reduces onboarding friction and accelerates tech transfer timelines.
For organizations requiring bulk quantities of high-purity 2,5-Dimercapto-1,3,4-thiadiazole with full regulatory backing, partnering with a vertically integrated manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. ensures both technical reliability and commercial agility. Their commitment to transparent COA practices, coupled with competitive bulk price structures, positions them as a strategic supplier for global API producers.
When sourcing high-purity 2,5-Dimercapto-1,3,4-thiadiazole, always request a sample COA prior to purchase to verify analytical rigor, method specificity, and alignment with your internal quality thresholds.